Aclaris Therapeutics Inc (ACRS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Aclaris Therapeutics Inc   (NASDAQ: ACRS)


Aclaris Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Aclaris Therapeutics Inc's ROI in the second quarter of 2026?
Aclaris Therapeutics Inc recorded a cumulative net loss of $-76 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -50.11%.

Within the Healthcare sector 463 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3591 to 3675.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -12.54 % -8.74 % -4.77 % 7.64 % 5.23 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 151 171 132 150 162
Return On Investment (TTM) -50.11 % -45.28 % -41.84 % -83.65 % -77.92 %
ACRS's Overall Ranking # 3675 # 3591 # 2602 # 3681 # 3222
Seq. Investment Change TTM -1.76 % -0.84 % -8.4 % -1.98 % 2.51 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -76 -70 -65 -142 -135




Return On Investment ACRS's Ranking
Within: No.
Industry # 195
Sector # 464
Overall # 3675

Return On Investment Statistics
High Average Low
155.35 %
-46.94 %
-124.44 %
(Dec 31 2015)   (Mar 31 2020)







Financial Statements
Aclaris Therapeutics Inc's II. Quarter Investments $ 151 Millions ACRS's Balance sheet
Aclaris Therapeutics Inc's II. Quarter Income $ -22 Millions Quarterly ACRS's Income Statement
ACRS's Income by Division See ACRS's Income by Division


ACRS Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 132 189 166 233 228
Y / Y Investment Growth -30.16 % 13.38 % -28.46 % 2.08 % 310.34 %
Net Income in Millions -65 -132 -88 -87 -91
Y / Y Net Income Growth - - - - -
Annual Return On Investment -49.25 % -69.98 % -53.16 % -37.35 % -39.87 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ACRS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ACRS's Competitors
Subscribers only: Roi for Aclaris Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ACRS's Customers

Other Ratios
ACRS's Roa ACRS's Inventory Turnover Ratio ACRS's Growth Rates ACRS's Dividend Statistics
ACRS's Profitability Ratios ACRS's Asset Turnover Ratio ACRS's Dividend Growth
ACRS's Roe ACRS's Valuation Ratios ACRS's Financial Strength Ratios ACRS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-26T07:27:14+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.